Thinq Pharma-Cro Limited, a active public limited company, was established on 10 November 2006 in Mumbai, Maharashtra, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24239MH2006PLC165473. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹2.50 M and a paid-up capital of ₹0.50 M.
It upholds a compliant status. Employing 148 professional, Its leadership includes Chandrashekhar Shankar Nadkarni (Managing Director), Ravindra Ramakant Gulgule (Director), Rohit Ramakant Gulgule (Director). Past directors included Girish Suresh Virkar, Shibani Chandrashekhar Nadkarni. It holds ₹48.38 Cr open charges and ₹85.95 Cr settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at D-3 1St Floor, Daginawala Mansion S. B. Rd Mahim - West, Mumbai, Maharashtra, 400016.
U24239MH2006PLC165473
165473
10 November 2006
₹2.50 M
₹0.50 M
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Thinq Pharma-Cro Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Chandrashekhar Shankar Nadkarni | Managing Director | 10 Nov 2006 | Current |
| Ravindra Ramakant Gulgule | Director | 15 Sep 2011 | Current |
| Rohit Ramakant Gulgule | Director | 10 Nov 2006 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 30 Sep 2011 | Past |
| Pramod Abcsdd | Director | 18 May 2024 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Thinq Pharma-Cro Limited, for the financial year ended 2024, experienced significant reduction in revenue, with a 11.62% decrease. The company also saw a substantial fall in profitability, with a 17.22% decrease in profit. The company's net worth Soared by an impressive increase of 20.8%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2024, Thinq Pharma-Cro had a promoter holding of 96.00% and a public holding of 4.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹483,821,000.00
₹859,500,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Oct 2025 | Others | ₹1.44 Cr | Open |
| 30 Oct 2025 | Standard Chartered Bank | ₹8.50 Cr | Open |
| 17 Jun 2025 | Standard Chartered Bank | ₹12.00 Cr | Open |
| 30 Jan 2025 | Others | ₹7.42 M | Open |
| 08 Feb 2024 | Others | ₹5.70 Cr | Open |
Explore comprehensive loan charge details -
Thinq Pharma-Cro has a workforce of 148 employees as of Nov 07, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Thinq Pharma-Cro, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Thinq Pharma-Cro's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on A charge with Others amounted to Rs. 14.40 M with Charge ID 101203004 was registered on 31 Oct 2025. was documented.
Progress on A charge with Standard Chartered Bank amounted to Rs. 85.00 M with Charge ID 101182815 was registered on 30 Oct 2025. was documented.
Progress on Thinq Pharma-Cro Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was documented.
Progress on A charge registered on 02 Jan 2018 via Charge ID 100183710 with Hdfc Bank Limited was fully satisfied on 19 Jul 2025. was documented.
The activity A charge registered on 09 Nov 2017 via Charge ID 100136569 with Hdfc Bank Limited was fully satisfied on 19 Jul 2025. was completed.
A charge with Standard Chartered Bank amounted to Rs. 120.00 M with Charge ID 101125446 was registered on 17 Jun 2025. was recorded as a recent event.
The CIN of Thinq Pharma-Cro Limited is U24239MH2006PLC165473.
Thinq Pharma-Cro Limited is headquartered at D-3 1St Floor, Daginawala Mansion S. B. Rd Mahim - West, Mumbai, Maharashtra, 400016.
Thinq Pharma-Cro Limited was incorporated on 10 November 2006.
The current directors of Thinq Pharma-Cro Limited are
The primary industry of Thinq Pharma-Cro Limited is Manufacturing.
Thinq Pharma-Cro Limited is unlisted.
The authorized capital of Thinq Pharma-Cro Limited is ₹2.50 M, and the paid-up capital is ₹0.50 M.
The compliance status of Thinq Pharma-Cro Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX